Mitsubishi UFJ Asset Management UK Ltd. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 90.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the medical device company’s stock after selling 19,000 shares […]
2023 wasn't a good year for the health-care sector, but some investors expect it to rebound this year highlighting biotech and medical tech as areas to watch.
Investors bailed on many med-tech companies last year, fearing that the frenzy surrounding GLP-1 agonists would tank companies in the weight-loss, diabetes and orthopedics segments. Their concerns now appear overblown in many instances, with some of the most directly affected businesses reporting a “rising tide” associated with an increased focus on obesity treatment that has lifted their boats rather than sinking them.
EDINBURGH, Scotland - DexCom, Inc. , a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring System now.